BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VEGF Trap-Eye: Additional Phase II data

Additional data from the double-blind, international Phase II DA VINCI trial in 219 patients showed that all 4 doses of intravitreal VEGF Trap-Eye maintained significant improvements from baseline to week 52 vs. macular laser therapy (p<0.01 for all). Specifically, 0.5 and 2 mg monthly VEGF Trap-Eye led to mean gains from baseline to week 52 in BCVA score of...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >